tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ImmuneOnco Receives $10 Million Milestone Payment for Cancer Therapy Development

Story Highlights
ImmuneOnco Receives $10 Million Milestone Payment for Cancer Therapy Development

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an update.

ImmuneOnco Biopharmaceuticals has announced the receipt of a $10 million milestone payment from Instil Bio, following FDA clearance to initiate a Phase I clinical trial for their bispecific antibody IMM2510/AXN-2510. This payment marks a significant step in the collaboration between the two companies, highlighting their commitment to advancing cancer therapies and potentially strengthening ImmuneOnco’s position in the biopharmaceutical industry.

More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company specializes in creating bispecific antibodies, such as IMM2510/AXN-2510, which target PD-L1 and VEGF for the treatment of multiple solid tumor cancers.

Average Trading Volume: 4,925,840

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.92B

For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1